SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

June 30, 2015 07:00 ET

CTD Holdings Ships Additional Trappsol® Cyclo™ to Brazil

Trappsol® Cyclo™ Is the Exclusive Form of Hydroxylpropyl Beta Cyclodextrin Purchased by the Government of Brazil for the Treatment of Niemann-Pick Type C

ALACHUA, FL--(Marketwired - June 30, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that the company is shipping 608 additional vials of its Trappsol® Cyclo product to the government of Brazil under a business relationship now in its fifth year.

CTD's orphan drug designated Trappsol® Cyclo is being developed for the treatment of Niemann-Pick Type C (NPC), a rare and fatal disease found primarily in children. It is being used as an investigational new drug for the treatment of NPC in the US, Europe and Brazil.

CTD has an exclusive supplier agreement with the government of Brazil and distributes to the country through its exclusive distribution partner UnoHealthcare of Miami, FL. Trappsol® Cyclo is the only commercial product to hold EMA and FDA Orphan Drug Designation as a treatment for NPC.

When the current shipment is completed, CTD will have supplied nearly 5,000 vials of liquid Trappsol® Cyclo and more than 170 kg of powdered first generation product to the government in Brazil for treatment of NPC. CTD has been supplying Trappsol® Cyclo to Brazil for treatment of NPC since 2010. Treatment of NPC patients in Brazil is under the direct care of their physicians and in conformance with all regulatory requirements of the Brazilian Health Survey Agency (ANVISA).

"We are grateful to be able to supply Brazilian NPC patients with Trappsol® Cyclo," stated CTD President & CEO Dr. Jeffrey Tate, "Our exclusive agreement with UnoHealthcare for distribution in Brazil has been instrumental in getting this product in the hands of physicians for the benefit of their NPC patients."

About CTD Holdings, Inc.:
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo, an orphan drug designated product, for the treatment of Niemann-Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of UltraPure cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial-scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com.

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information